A Study to Learn if Taking BIIB141 (Omaveloxolone) Affects How Omeprazole is Processed in the Body and About BIIB141's Safety in Healthy Adults Aged 18 to 55

NCT07149415 | Completed Phase 1 FDA Drug

• 1 other identifier: 296HV104
• Study Type: interventional
• Target: 22
• Locations: 1 country
• Sites: 1

Brief Summary

In this study, researchers will learn more about BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedrich's Ataxia (FA) who are at least 16 years old. This is called a "drug-drug interaction" study. In this kind of study, researchers are looking at what happens when 2 or more medicines affect each other in the body. This could change how 1 or both of the drugs work, either making them stronger, weaker, or causing health problems. The main goal of this study is to learn if taking BIIB141 affects how omeprazole is processed in the body. Omeprazole is a commonly used medicine to help lower the amount of acid the stomach makes. The main question researchers want to answer in this study is :

• How does the body process omeprazole when taken with BIIB141? Researchers will also learn more about :
• How many participants have adverse events during the study. An adverse event is a health problem that may or may not be caused by the study drug.
• How many participants have adverse reactions during the study. An adverse reaction is a health problem that may be caused by the study drug.
• If there are any changes in the participants' overall health during the study. This study will be done as follows:
• Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center.
• Participants will stay at the study research center for about 17 days.
• This is an "open label" study. In this kind of study, the participants, study doctor, and site staff know which study drug the participant is taking. In this study, all participants took BIIB141 and omprezole.
• Participants will take omeprazole on Day 1 and Day 16. They will also take BIIB141 once a day from Day 2 through Day 16.
• Throughout the study, researchers will take participants' blood and urine samples. Researchers will also do other tests to check the participants' overall health and will ask participants how they are feeling.
• Each participant will be in the study for up to 45 days.

Conditions

Healthy Volunteer

Outcome Measures

Primary Outcomes (2)

• Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Omeprazole

  Pre-dose and at multiple timepoints post-dose on Days 1, 2, 16 and 17

• Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Omeprazole

  Pre-dose and at multiple timepoints post-dose on Days 1, 2, 16 and 17

Secondary Outcomes (5)

• Maximum Observed Plasma Concentration (Cmax) of Omeprazole

  Pre-dose and at multiple timepoints post-dose on Days 1, 2, 16 and 17

• Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  From Day 1 up to end of the study (Up to Day 17)

• Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities

  From Day 1 up to end of the study (Up to Day 17)

• Number of Participants With Change From Baseline in Clinically Relevant Abnormalities in Vital Sign Parameters

  From Day 1 up to end of the study (Up to Day 17)

• Number of Participants With Change From Baseline in Clinically Relevant Abnormalities in Electrocardiogram (ECG) Parameters

  From Day 1 up to end of the study (Up to Day 17)

Study Arms (2)

Period 1: Omeprazole

EXPERIMENTAL

Participants will receive a single oral dose of omeprazole on Day 1.

Drug: Omeprazole

Period 2: Omaveloxolone + Omeprazole

EXPERIMENTAL

Participants will receive omaveloxolone from Days 2 to 15, followed by both omaveloxolone and omeprazole on Day 16.

Drug: Omaveloxolone; Drug: Omeprazole

Interventions

Omaveloxolone DRUG

Oral capsules

Also known as: BIIB141, RTA-408

Period 2: Omaveloxolone + Omeprazole

Omeprazole DRUG

Oral tablet

Period 1: Omeprazole; Period 2: Omaveloxolone + Omeprazole

Eligibility Criteria

• Age: 18 Years - 55 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• All female participants of childbearing potential must have negative results for pregnancy tests as follows:
• At screening, based on a serum sample obtained within 28 days prior to initial study drug administration; and
• Prior to dosing, based on a serum sample obtained on Study Day -1.
• Body mass index (BMI) at screening between 18 and 32 kilograms per square meter (kg/m\^2), inclusive.

You may not qualify if:

• History of any clinically significant cardiac, endocrine, gastrointestinal, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, or renal disease, or other major disease, as determined by the Investigator.
• Clinically significant, as determined by the Investigator, 12-lead electrocardiogram (ECG) abnormalities.
• History of, or positive test result at Screening for, human immunodeficiency virus (HIV).
• History of hepatitis C infection or positive test result at Screening for hepatitis C virus antibody (HCV Ab).
• Current hepatitis B infection \[defined as positive for hepatitis B surface antigen (HBsAg) and/or total anti-HBc\]. Participants with immunity to hepatitis B from previous natural infection (defined as negative HBsAg, positive anti-HBc, and positive anti-HBs) or vaccination (defined as negative HBsAg, negative anti-HBc, and positive anti-HBs) are eligible to participate in the study.
• Chronic, recurrent, or serious infection (e.g., pneumonia, septicemia, and herpes simplex virus), as determined by the Investigator, within 90 days prior to Screening or between Screening and Day -1.
• Symptoms of bacterial, fungal, or viral infection (including upper respiratory tract infection) within 14 days prior to Screening or between Screening and Day -1. Participants with local fungal infection (e.g., candidiasis, tinea) are eligible to be rescreened after successful treatment of the infection.
• Prior exposure to omaveloxolone.

Sponsors & Collaborators

• Biogen: lead

Study Sites (1)

Austin Clinical Research Unit

Austin, Texas, 78744, United States

Location

MeSH Terms

Interventions

omaveloxolone; Omeprazole

Intervention Hierarchy (Ancestors)

2-Pyridinylmethylsulfinylbenzimidazoles; Sulfoxides; Sulfur Compounds; Organic Chemicals; Pyridines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Benzimidazoles; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Officials

• Medical Director

  Biogen

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 28, 2025
• First Posted: September 2, 2025
• Study Start: September 2, 2025
• Primary Completion: October 16, 2025
• Study Completion: October 16, 2025
• Last Updated: October 23, 2025

Record last verified: 2025-10

Data Sharing

• IPD Sharing: Will share

Locations

US (1)